Most viewed in 2019
Unlock full
details of
this profile
with our freeLiteplan!
Signup and get free access
Last updated:
Claim ProfileSuggest Edits
- Request page removal
Spectrum Pharmaceuticals - About the company
Spectrum Pharmaceuticals is an acquired company based in Henderson (United States), founded in 1987
.
It operates as a Developer of small molecule therapeutics for oncology and hematology
.
Spectrum Pharmaceuticals has raised an undisclosed amount in funding
.
The company has 2998 active competitors, including 1050 funded and 706 that have exited
. Its top competitor
s
include companies like Jazz Pharmaceuticals, Moderna and BeiGene.
Company Details
Developer of small molecule therapeutics for oncology and hematology. The company's product line includes 'Rolvedon' for non-myeloid malignancies and Poziotinib an orally administered, irreversible tyrosine kinase inhibitor (TKI) for the treatment of solid tumors.
Key Metrics
Founded Year
1987
Location
Henderson,
United States
Stage
Acquired
Latest Funding Round
Investors
Tekla Capital Management
&
2 moreRanked
768th
among
2998 active competitors
Annual Revenue
$28.6M
as on Dec 31, 2017
Employee Count
164
as on Dec 31, 2021
Similar Companies
Jazz Pharmaceuticals
&
2919 moreExit Details
Acquired
by
Assertio (Apr 25, 2023)
Legal entities associated with Spectrum Pharmaceuticals
Spectrum Pharmaceuticals
is associated with
2
legal entit
ies
given below:
Legal Entity Name | Date of incorporation | Revenue | Net Profit | Employee Count |
|---|---|---|---|---|
SPECTRUM PHARMACEUTICALS INC | May 06, 1997 | $28.6M (as on Dec 31, 2017) | 939 | 181 |
Spectrum Pharmaceuticals, Inc | Dec 31, 1986 | - | 837 | 852 |
Get your free copy of Spectrum Pharmaceuticals's company profile
Spectrum Pharmaceuticals's acquisition details
Spectrum Pharmaceuticals
got acquired
by Assertio on
Apr 25, 2023
.
It was facilitated by
Guggenheim Partners
,
Gibson Dunn
,
H.C. Wainwright & Co
and
3 more.
Click
here
to take a look at
Spectrum Pharmaceuticals
's acquisition in detail
Spectrum Pharmaceuticals's funding and investors
Filter this list
Spectrum Pharmaceuticals has raised funding over 15 rounds. Its first funding round was on Nov 22, 2002. Its latest funding round was a Post IPO round on Jan 04, 2022 for $20M. 1 investor participated in its latest round, which include Tekla Capital Management, Perceptive Advisors and Hanmi Pharmaceuticals.
Spectrum Pharmaceuticals has 3 institutional investors including Tekla Capital Management, Perceptive Advisors and Hanmi Pharmaceuticals.
Here is the list of recent funding rounds of
Spectrum Pharmaceuticals
:
Date of funding | Funding Amount | Round Name | Post money valuation | Revenue multiple | Investors |
|---|---|---|---|---|---|
Jan 04, 2022 | $20M | Post IPO | 3277587 | 9921004 | Hanmi Pharmaceuticals |
Apr 26, 2016 | $3M | Post IPO | 8681188 | 2481963 | - |
Jul 07, 2013 | $27.5M | Post IPO | 5325689 | 3070069 | - |
Access funding benchmarks and valuations.
Sign up today!
View details of
Spectrum Pharmaceuticals's funding rounds and investorsSpectrum Pharmaceuticals's founders and board of directors
Founder? Claim Profile
Spectrum Pharmaceuticals's employee count trend
Spectrum Pharmaceuticals has 164 employees as of Dec 21. The total employee count is 6.8% lower than what it was in Dec 20.
Here is
Spectrum Pharmaceuticals
's employee count trend over the years:
Uncover Spectrum Pharmaceuticals's growth story!
Sign up today!
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Spectrum Pharmaceuticals's Competitors and alternates
Top competitor
s
of
Spectrum Pharmaceuticals
include
Jazz Pharmaceuticals, Moderna and BeiGene.
Here is the list of Top 10 competitors of
Spectrum Pharmaceuticals
, ranked by Tracxn score :
Overall Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |
Jazz Pharmaceuticals 2003 , Dublin (Ireland) , Public | Developer of therapeutics for cancer and neurological disorders | $265M | InterWest Partners, Investor Growth Capital& 14others | 85/100 |
2nd |
Moderna 2010 , Cambridge (United States) , Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | Flagship Pioneering, Wellington& 29others | 85/100 |
3rd |
BeiGene 2010 , Cambridge (United States) , Public | Developer of targeted and immune-oncology drugs against cancer | $172M | T. Rowe Price, Temasek& 13others | 84/100 |
4th |
Advanced Accelerator Applications 2002 , Saint Genis Pouilly (France) , Acquired | Novartis company, developing molecular nuclear medicine theranostics | $56.1M | Vivo Capital, HBM Partners& 4others | 82/100 |
5th |
Recursion 2013 , United States, Public | R&D based company focused on manufacturing of drugs for multiple therapeutic areas | $452M | HTIF, Menlo Ventures& 45others | 81/100 |
6th |
Incyte 1991 , Wilmington (United States) , Public | Developer of small molecules for the treatment of different cancer and skin diseases | - | Tekla Capital Management, Ridgeback Capital Management& 5others | 78/100 |
7th |
Revolution Medicines 2014 , Redwood City (United States) , Public | Developer of therapies for treating cancer | $181M | Vivo Capital, Deerfield& 12others | 78/100 |
8th |
Blueprint Medicines 2008 , Cambridge (United States) , Public | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | Ridgeback Capital Management, Foresite Capital& 19others | 76/100 |
9th |
Syndax 2005 , Waltham (United States) , Public | Developer of targeted therapies for the treatment of cancer | $198M | Aisling Capital, Frazier Healthcare Partners& 19others | 76/100 |
10th |
C4 Therapeutics 2016 , Cambridge (United States) , Public | Developer of small molecule drugs for treating cancer | $223M | Roche, Perceptive Advisors& 25others | 75/100 |
768th |
Spectrum Pharmaceuticals 1987 , Henderson (United States) , Acquired | Developer of small molecule therapeutics for oncology and hematology | - | Tekla Capital Management, Perceptive Advisors& 1others | 42/100 |
Get insights and benchmarks for competitors of 2M+ companies!
Sign up today!
Looking for more details on
Spectrum Pharmaceuticals
's competitors? Click
here to see the top ones
Spectrum Pharmaceuticals's Investments and acquisitions
Spectrum Pharmaceuticals
has made no investments or acquisitions yet.
Reports related to Spectrum Pharmaceuticals
Here is the latest report on Spectrum Pharmaceuticals's sector:
View
all reports related to Spectrum PharmaceuticalsNews related to Spectrum Pharmaceuticals
Filter this list
•
BPGbio Appoints Ritesh Srivastava as General CounselBioSpace•Jan 22, 2024•BPGbio,
Spectrum Pharmaceuticals
•
Janney Montgomery Scott LLC Buys Shares of 143,186 Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)etfdailynews.com•Aug 11, 2023•Janney,
Spectrum Pharmaceuticals
•
Assertio Holdings, Inc. Announces Favorable Vote on Proposed Acquisition of Spectrum PharmaceuticalsGlobeNewswire•Jul 28, 2023•Spectrum Pharmaceuticals
, Assertio
•
Halper Sadeh LLC Is Investigating Whether the Merger of Assertio Holdings, Inc. Is Fair to ShareholdersBusiness Wire•Jun 07, 2023•Halper Sadeh, Assertio,
Spectrum Pharmaceuticals
•
Spectrum Pharmaceuticals regains compliance with Nasdaq minimum bid price requirementSeeking Alpha•May 17, 2023•Spectrum Pharmaceuticals
•
Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price RequirementBusiness Wire•May 17, 2023•Spectrum Pharmaceuticals
•
Spectrum Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate UpdateBusiness Wire•May 09, 2023•Spectrum Pharmaceuticals
•
Assertio to Acquire Spectrum Pharmaceuticals in All Stock and Cvr TransactionPharma Business International•May 03, 2023•Assertio,
Spectrum Pharmaceuticals
•
Weiss Law Reminds SPPI, NATI, CCFN, and ARST Shareholders About Its Ongoing InvestigationsPR Newswire•May 02, 2023•Weiss Law,
Spectrum Pharmaceuticals
, National Instruments Corporation, Assertio
•
The M&A Class Action Firm Continues the Investigation of the MergerGlobeNewswire•Apr 27, 2023•Monteverde, Muncy Bank, Prometheus Biosciences,
Spectrum Pharmaceuticals
and 1 other
Get curated news about company updates, funding rounds, M&A deals and others.
Sign up today!
Our Lite Plan Awaits you -
Its Free!
Sign up now to unlock full access to curated data
- 4M+ Companies
- 212K+ Investors
- 580K+ Funding Rounds
- 207K+ Acquisitions
- 2.9K+ Sectors
- 57K+ Business Models
Signup and get free access
Are you a Founder ?
FAQ's about Spectrum Pharmaceuticals
Spectrum Pharmaceuticals was founded in 1987.
Spectrum Pharmaceuticals
is located in
Henderson,
United States.
Spectrum Pharmaceuticals has 164 employees as of Dec 31, 2021.
Spectrum Pharmaceuticals's latest funding round was on Jan 04, 2022.
Spectrum Pharmaceuticals ranks 768 amongst 2998 active competitors.
Developer of small molecule therapeutics for oncology and hematology. The company's product line includes 'Rolvedon' for non-myeloid malignancies and Poziotinib an orally administered, irreversible tyrosine kinase inhibitor (TKI) for the treatment of solid tumors.
Joseph Turgeon
is
the current CEO of
Spectrum Pharmaceuticals
.
Spectrum Pharmaceuticals got acquired by Assertio on Apr 25, 2023.
Annual revenue of Spectrum Pharmaceuticals is $28.6M as on Dec 31, 2017.
Spectrum Pharmaceuticals'
top competitor
s are Jazz Pharmaceuticals, Moderna and BeiGene.
Explore our recently published companies
- Example Company - Indore based, Unfunded company
- Drags Finserv - Navi Mumbai based, 2017 founded, Unfunded company
- Jobois - Unfunded company
- Formli - Unfunded company
- MG Web Lab Limited - 2017 founded, Unfunded company
- Oxford Arts - Unfunded company
